Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995 Sep;29(3):192–209. doi: 10.2165/00003088-199529030-00005. [DOI] [PubMed] [Google Scholar]
- Brøsen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol. 1989;36(6):537–547. doi: 10.1007/BF00637732. [DOI] [PubMed] [Google Scholar]
- Cleary J., Mikus G., Somogyi A., Bochner F. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. J Pharmacol Exp Ther. 1994 Dec;271(3):1528–1534. [PubMed] [Google Scholar]
- Eichelbaum M., Gross A. S. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. Pharmacol Ther. 1990;46(3):377–394. doi: 10.1016/0163-7258(90)90025-w. [DOI] [PubMed] [Google Scholar]
- Kobayashi S., Murray S., Watson D., Sesardic D., Davies D. S., Boobis A. R. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol. 1989 Sep 1;38(17):2795–2799. doi: 10.1016/0006-2952(89)90433-4. [DOI] [PubMed] [Google Scholar]
- Otton S. V., Schadel M., Cheung S. W., Kaplan H. L., Busto U. E., Sellers E. M. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993 Nov;54(5):463–472. doi: 10.1038/clpt.1993.177. [DOI] [PubMed] [Google Scholar]
- Otton S. V., Wu D., Joffe R. T., Cheung S. W., Sellers E. M. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther. 1993 Apr;53(4):401–409. doi: 10.1038/clpt.1993.43. [DOI] [PubMed] [Google Scholar]